Genome-scale CRISPR-Cas9 knockout studies to characterize the mechanisms of myeloma cell treatment resistance.

OP-001 A Meta-Analysis Investigating the Impact of Minimal Residual Disease (MRD) Status on Survival Outcomes in Patients With Multiple Myeloma (MM) who Achieve Complete Response (CR) N. Munshi, H. Avet-Loiseau, A. Rawstron, R. Owen, A. Thakurta, P. Sherrington, A. Georgieva, K. Anderson, W. Gregory Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, France; St James’s University Hospital, Leeds, United Kingdom; Celgene Corporation, Summit, NJ, USA; Celgene International, Boudry, Switzerland; Excerpta Medica, Amsterdam, Netherlands; University of Leeds, Leeds, United Kingdom